Brain

FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience

The Sontag Innovation Fund and the Yuvaan Tiwari Foundation join Two Bear Capital to support FYR's growing oncology portfolio and…

5 months ago

NUCALM IGNITES THE POWER OF VOICE WITH CELEBRATED COACH ROGER LOVE

Harnessing Neuroscience and Voice Mastery to Transform How Humans Communicate and Connect LOS ANGELES, Sept. 24, 2025 /PRNewswire/ -- NuCalm®,…

5 months ago

A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients

Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's…

5 months ago

A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients

Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's…

5 months ago

EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain Function and Stimulation

Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research EGI GES 500 Next-Generation HD-EEG Platform…

5 months ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…

5 months ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by…

5 months ago

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis…

5 months ago

Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults…

5 months ago